SAN DIEGO, March 12, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced positive interim results from a Phase II proof-of-concept study evaluating the safety, ...
Narrative Review Assesses Current Treatment Challenges and the Evolving Classic Congenital Adrenal Hyperplasia (CAH) Therapeutic Landscape Non-Glucocorticoid (GC) Mechanisms for Treatment of CAH Could ...
The FDA accepted Neurocrine Bioscience's new drug applications with priority review for crinecerfont, an investigational treatment for pediatric and adult patients with classic congenital adrenal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results